Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of “Moderate Buy” from Brokerages
Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) have received an average recommendation of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price […]
Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) have received an average recommendation of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price […]
